Bispecific antibody · Agonist of CD40 and 4-1BB (CD137) (TNFRSF9) · developed by Genmab
Tecaginlimab (GEN1042) is a humanized, Fc-silenced bispecific agonistic antibody that binds both CD40 and 4-1BB (TNFRSF9) and crosslinks cells expressing them. It activates CD40 signaling in antigen-presenting cells and 4-1BB signaling in T cells to enhance cytotoxic T-lymphocyte responses against tumor cells. It is being studied in non-CNS tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05491317 | Phase 1/2 | Non-CNS Tumor | Terminated | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non-CNS Tumor
See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GMAB catalysts and pipeline →